ClinicalTrials.gg
RecruitingNCT06352307STARTERUpdated Nov 18, 2026

Clinical Phenotypes, Natural History, and Long-Term Outcomes of Arrhythmogenic Cardiomyopathy: The STARTER Registry

An observational study in Arrhythmogenic Cardiomyopathy, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Nov 18, 2026Primary completion movedStudy completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
4,500
Sex
All
01

Study summary

The goal of this observational study is to describe the clinical phenotypes, natural history, and long-term outcomes of arrhythmogenic cardiomyopathy (ACM) in patients of all ages.

The main questions it aims to answer are:

  • How do the clinical characteristics and disease phenotypes of patients with ACM change over time?
  • How often do patients with ACM experience serious ventricular arrhythmias, sudden cardiac death, heart failure, and other major clinical outcomes during long-term follow-up?
  • How do clinical, imaging, and genetic characteristics differ among patients with right-dominant, left-dominant, and biventricular ACM?

Researchers will observe patients with different ACM phenotypes to better understand their disease progression and long-term outcomes. No experimental treatments will be assigned.

Participants will:

  • Have their existing medical records, clinical examinations, cardiac imaging, electrocardiographic findings, genetic test results (when available), and treatments reviewed.
  • Be followed for up to 5 years through routine clinical visits, medical records, or telephone contacts, with extended follow-up when applicable.
  • Optionally provide biological samples during routine clinical care, with appropriate informed consent. Providing samples is not required to participate in the study.
Read the detailed description

Background and Rationale

Arrhythmogenic cardiomyopathy (ACM) is a heterogeneous group of myocardial diseases characterized by a predisposition to ventricular arrhythmias, sudden cardiac death, and progressive ventricular dysfunction. ACM may predominantly affect the right ventricle, left ventricle, or both ventricles. Its clinical manifestations, genetic backgrounds, patterns of myocardial involvement, and rates of disease progression vary considerably among affected individuals.

Despite advances in genetic testing, cardiac imaging, and clinical management, the natural history and long-term outcomes of ACM remain incompletely characterized, particularly across different ventricular phenotypes, age groups, and genetic backgrounds. Longitudinal multicenter data are needed to better understand disease progression, major ventricular arrhythmic events, heart failure-related outcomes, and changes in cardiac structure and function.

Study Objectives

The STARTER Registry aims to systematically characterize the clinical phenotypes, natural history, and long-term outcomes of patients with ACM. Particular emphasis is placed on serious ventricular arrhythmias, sudden cardiac death, heart failure-related events, and longitudinal changes in ventricular structure and function.

The study also aims to establish a standardized clinical database linked to an optional biological sample repository to support future clinical and translational research, subject to appropriate ethical approval and participant authorization.

Study Design and Population

STARTER is an investigator-initiated, multicenter, observational, retrospective and prospective registry cohort study led by the First Affiliated Hospital of Xi'an Jiaotong University.

The registry will include approximately 4,500 patients with a clinical diagnosis of ACM, without restrictions on age or sex. Eligible patients include those previously diagnosed with ACM, those currently receiving follow-up care, and newly diagnosed patients.

The diagnosis of ACM will be established through comprehensive clinical evaluation, incorporating medical and family history, electrocardiographic findings, cardiac imaging, genetic testing when available, and histopathological findings when clinically indicated. Diagnostic assessment will refer to established international guidelines and consensus documents, including the 2019 Heart Rhythm Society expert consensus statement, the 2020 Padua criteria, the 2023 European Society of Cardiology guidelines for cardiomyopathies, and applicable updated diagnostic standards.

Patients will be primarily classified into three ventricular phenotype categories:

  • Right-dominant ACM.
  • Left-dominant ACM.
  • Biventricular ACM.

Additional analyses may examine differences according to genetic background, age, ventricular arrhythmia history, cardiac magnetic resonance findings, ventricular function, and clinical disease stage. These classifications are observational and do not determine treatment allocation.

Retrospective and Prospective Cohorts

The retrospective component will include eligible patients with available clinical records from January 1, 2018, through October 1, 2026. Previously collected clinical information, diagnostic investigations, treatment records, and documented clinical outcomes will be reviewed.

The prospective component will enroll eligible patients following the required ethical approvals and will continue recruitment through December 31, 2045.

Each patient will generally undergo a core observation period of 5 years, with follow-up assessments at approximately 6 months, 12 months, and annually during years 2 through 5. Extended follow-up may be conducted when applicable,

02

Conditions studied

  • Arrhythmogenic Cardiomyopathy

Keywords

  • Arrhythmogenic Right Ventricular Cardiomyopathy
  • Arrhythmogenic Left Ventricular Cardiomyopathy
  • Biventricular Arrhythmogenic Cardiomyopathy
  • Ventricular Arrhythmias
  • Sudden Cardiac Death
  • Clinical Phenotypes
  • Natural History
  • Long-Term Outcomes
  • Genetics
  • Patient Registry
03

In context

Arrhythmogenic Right Ventricular Dysplasia

49 studies on the registry are indexed under Arrhythmogenic Right Ventricular Dysplasia; 29 are open to participants now.

This study's planned enrollment of 4,500 is above the median of 336 across 34 observational studies indexed under Arrhythmogenic Right Ventricular Dysplasia.

Browse Arrhythmogenic Right Ventricular Dysplasia studies →

Lead sponsor

First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 318 studies on the registry; 91 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of patients of all ages with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM) receiving care at the First Affiliated Hospital of Xi'an Jiaotong University and participating medical centers in China. The registry includes patients with previously established ACM, patients undergoing ongoing clinical follow-up, and newly diagnosed patients. Eligible participants will be identified through routine clinical practice and existing medical records. Both retrospective and prospective cohorts will be included. Patients may present with right-dominant, left-dominant, or biventricular ACM phenotypes. Enrollment does not require genetic testing, cardiac magnetic resonance imaging, or biological sample collection. Patients will be enrolled consecutively when eligible, and unique study identifiers will be used to avoid duplicate enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of any age or sex with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM), established through comprehensive clinical evaluation based on medical and family history, electrocardiographic findings, cardiac imaging, available genetic testing results, and histopathological findings when clinically indicated. Diagnosis will refer to applicable international guidelines and consensus documents, including the 2019 Heart Rhythm Society expert consensus statement, the 2020 Padua criteria, the 2023 European Society of Cardiology guidelines for cardiomyopathies, and subsequent applicable updates.
  2. Availability of essential clinical information sufficient to confirm the diagnosis of ACM and establish a longitudinal clinical record, including relevant baseline and observation dates.
  3. Fulfillment of applicable ethical approval and requirements. For retrospective data collection, participation will be subject to approved consent waiver provisions or existing valid authorization. Prospective participants will provide informed consent through the applicable approved procedures. For minors, permission from a parent or legal guardian and age-appropriate assent will be obtained as required.

Exclusion criteria

Exclusion Criteria:

  1. ACM diagnosis cannot be confirmed after clinical review, or the observed cardiac abnormalities and ventricular arrhythmias can be sufficiently explained by another established disease without meeting the study's diagnostic criteria for ACM.
  2. Insufficient essential clinical information to confirm ACM diagnosis or determine the relevant observation period, despite reasonable efforts to verify the available records.
  3. Refusal to participate, withdrawal or absence of required authorization, or failure to meet applicable ethical and requirements.

Additional Considerations:

Patients with coexisting diseases, previous ventricular arrhythmias, implantable cardioverter-defibrillators, prior catheter ablation, or heart failure may be eligible if they otherwise meet the study criteria.

Cardiac magnetic resonance imaging, genetic testing, and biological sample collection are not mandatory for enrollment. The absence of these investigations or samples will not be considered an exclusion criterion.

Asymptomatic relatives carrying ACM-associated genetic variants who do not meet the clinical diagnostic criteria for ACM will not be included in the confirmed ACM registry cohort solely on the basis of carrier status.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
4,500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Retrospective Cohort

    Patients of all ages with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM) and available medical records from January 1, 2018, through October 1, 2026, will be included retrospectively. Existing clinical data, including medical history, ventricular phenotype, electrocardiographic findings, cardiac imaging, genetic testing results when available, treatments, and documented clinical outcomes, will be collected and analyzed. Patients will be classified according to right-dominant, left-dominant, or biventricular ACM phenotypes. No research-specific interventions, additional examinations, or new biospecimen collection will be performed as part of retrospective data collection.

  • Prospective Cohort

    Patients of all ages with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM) will be prospectively enrolled and followed under routine clinical care. Clinical, electrocardiographic, imaging, genetic, treatment, and outcome data will be collected. Patients will be classified as having right-dominant, left-dominant, or biventricular ACM. Follow-up will generally occur at 6 months, 12 months, and annually during years 2 through 5 to assess serious ventricular arrhythmias, sudden cardiac death, heart failure-related events, and changes in cardiac phenotype. Optional biospecimens may be collected with appropriate consent and ethical approval. No experimental treatments or research-mandated invasive procedures will be performed.

06

What researchers measure

Primary outcomes

  1. Time to First Composite Serious Ventricular Arrhythmic Event

    Time from cohort entry to the first occurrence of a composite serious ventricular arrhythmic event, defined as sustained ventricular tachycardia (VT), ventricular fibrillation (VF), successfully resuscitated cardiac arrest, appropriate implantable cardioverter-defibrillator (ICD) therapy, or sudden cardiac death. Sustained VT is defined as lasting at least 30 seconds or requiring earlier termination because of hemodynamic instability. Appropriate ICD therapy includes antitachycardia pacing or shock delivered for a confirmed ventricular tachyarrhythmia. Events occurring before cohort entry will be recorded separately and will not be counted as incident events.

    Time frame: Time to First Composite Serious Ventricular Arrhythmic Event

Secondary outcomes

  1. First Occurrence of Sustained Ventricular Tachycardia or Ventricular Fibrillation

    Time from cohort entry to the first occurrence of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) during follow-up, documented by electrocardiography, ambulatory rhythm monitoring, implanted cardiac devices, or other available clinical records. Sustained VT is defined as lasting at least 30 seconds or requiring earlier termination because of hemodynamic instability. The date and type of the first qualifying event will be recorded.

    Time frame: 5 years

  2. Incidence of Sudden Cardiac Death

    Sudden cardiac death during follow-up, assessed using available medical records, circumstances of death, and other supporting clinical information. Events will be classified according to standardized adjudication criteria, including documented or clinically suspected sudden cardiac death when supported by available evidence.

    Time frame: 5 years

  3. First Occurrence of Appropriate Implantable Cardioverter-Defibrillator Therapy

    Time from cohort entry to the first occurrence of appropriate ICD therapy, including antitachycardia pacing or shock delivered for a documented ventricular tachyarrhythmia, as confirmed by available device interrogation records and clinical review. Inappropriate ICD therapies will not be counted. This outcome will be evaluated among patients with an ICD during the observation period.

    Time frame: 5 years

  4. Occurrence of Heart Failure Hospitalization

    Occurrence of hospitalization for worsening heart failure after cohort entry, identified from hospital records and follow-up information. Heart failure hospitalization will be evaluated as a separate clinical outcome, with the date of the first qualifying admission recorded.

    Time frame: 5 years

  5. All-Cause Mortality

    Occurrence of death from any cause after cohort entry during follow-up. The date of death will be determined from available medical records, follow-up information, and other approved sources. All deaths will be included regardless of the underlying cause.

    Time frame: 5 years

  6. Cardiovascular Mortality

    Occurrence of death attributed to cardiovascular causes after cohort entry during follow-up. The date and cause of death will be determined using available medical records, follow-up information, and other supporting clinical information. Cardiovascular mortality will be classified separately from noncardiovascular mortality whenever sufficient information is available.

    Time frame: 5 years

  7. Occurrence of Heart Transplantation

    Occurrence of heart transplantation after cohort entry during follow-up, as documented in clinical records. The date of transplantation will be recorded.

    Time frame: 5 years

  8. Initiation of Long-Term Mechanical Circulatory Support

    Occurrence of implantation or initiation of long-term mechanical circulatory support after cohort entry during follow-up, as documented in clinical records. The date and type of mechanical circulatory support will be recorded.

    Time frame: 5 years

  9. Rate of Recurrent Serious Ventricular Arrhythmic Events

    Frequency and timing of recurrent sustained ventricular tachycardia, ventricular fibrillation, and appropriate ICD therapies after cohort entry during follow-up. Multiple qualifying events occurring in the same patient will be recorded. The number of recurrent events and event rates per person-year will be evaluated using appropriate recurrent-event statistical methods, subject to the availability and completeness of longitudinal clinical and device records. Event types will be documented separately.

    Time frame: 5 years

  10. Recurrence of Ventricular Arrhythmia After Catheter Ablation

    Occurrence of documented sustained ventricular tachycardia or ventricular fibrillation after clinically indicated catheter ablation among patients who undergo the procedure. Arrhythmia recurrence will be assessed using available electrocardiographic records, ambulatory rhythm monitoring, device interrogation, and clinical follow-up records. Catheter ablation is performed as part of routine clinical care and is not assigned by the study.

    Time frame: Up to 5 years

  11. Proportion of Patients With Changes in Ventricular Phenotype

    Changes in the predominant pattern of ventricular involvement in patients with arrhythmogenic cardiomyopathy, classified as right-dominant, left-dominant, or biventricular phenotype. The proportion of patients transitioning from one ventricular phenotype to another during follow-up will be assessed based on available clinical and imaging evaluations. Phenotype classification will follow the diagnostic criteria specified in the study protocol.

    Time frame: Baseline and up to 5 years

  12. Change in Left Ventricular Ejection Fraction

    Change in left ventricular ejection fraction (LVEF, %), assessed using serial echocardiography or cardiac magnetic resonance imaging performed during routine clinical care. Baseline and subsequent measurements obtained using comparable imaging modalities will be compared to evaluate changes in left ventricular systolic function. Analyses will account for the imaging modality used.

    Time frame: Baseline and up to 5 years

  13. Change in Right Ventricular Ejection Fraction

    Change in right ventricular ejection fraction (RVEF, %), assessed using serial cardiac magnetic resonance imaging when available. Baseline and subsequent RVEF measurements will be compared to characterize longitudinal changes in right ventricular systolic function. Analyses will be restricted to participants with available comparable serial imaging data.

    Time frame: Baseline and up to 5 years

  14. Change in Left Ventricular End-Diastolic Volume Index

    Change in left ventricular end-diastolic volume index (LVEDVi, mL/m²), assessed using cardiac magnetic resonance imaging when available. Baseline and subsequent measurements will be compared to characterize longitudinal changes in left ventricular size and remodeling. Analyses will be restricted to participants with available comparable serial imaging data.

    Time frame: Baseline and up to 5 years

  15. Change in Right Ventricular End-Diastolic Volume Index

    Change in right ventricular end-diastolic volume index (RVEDVi, mL/m²), assessed using cardiac magnetic resonance imaging when available. Baseline and subsequent measurements will be compared to characterize longitudinal changes in right ventricular size and remodeling. Analyses will be restricted to participants with available comparable serial imaging data.

    Time frame: Baseline and up to 5 years

  16. Presence of Late Gadolinium Enhancement on Cardiac Magnetic Resonance Imaging

    Presence or absence of late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging during follow-up. Changes in LGE status from baseline will be evaluated among participants with available comparable serial cardiac magnetic resonance imaging examinations.

    Time frame: Baseline and up to 5 years

  17. Ventricular Distribution of Late Gadolinium Enhancement

    Distribution of late gadolinium enhancement on cardiac magnetic resonance imaging, classified according to the ventricular region involved, including right ventricular, left ventricular, or biventricular involvement, based on available imaging assessments. Longitudinal changes in the distribution of LGE will be evaluated among participants with available comparable serial imaging examinations.

    Time frame: Baseline and up to 5 years

Other outcomes

  1. Associations Between Biospecimen-Derived Molecular Profiles and Clinical Outcomes

    Exploratory assessment of associations between molecular characteristics derived from appropriately authorized biological samples and clinical outcomes in patients with arrhythmogenic cardiomyopathy. Depending on sample availability and separately approved research protocols, analyses may include genetic, proteomic, metabolomic, or other molecular measurements. Each molecular measurement will be analyzed separately according to its specific assay and measurement scale. Associations with serious ventricular arrhythmic events, sudden cardiac death, heart failure-related outcomes, and clinical disease phenotypes may be explored. Analyses will be restricted to participants with available, appropriately authorized samples and relevant clinical data.

    Time frame: Baseline and up to 5 years

  2. Exploratory Molecular Signatures Associated With Ventricular Remodeling and ACM Phenotypes

    Exploratory characterization of molecular signatures potentially associated with myocardial remodeling and clinical phenotype heterogeneity in arrhythmogenic cardiomyopathy. Where appropriately authorized tissue or other biological samples and relevant clinical data are available, separately approved analyses may investigate molecular pathways related to myocardial fibrosis, inflammation, cellular stress, and metabolic remodeling. Findings may be compared across right-dominant, left-dominant, and biventricular ACM phenotypes and examined in relation to available cardiac imaging and longitudinal clinical characteristics. Different molecular measurements will be analyzed separately according to the methods used. No additional invasive procedures will be performed solely for these analyses.

    Time frame: Baseline and up to 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2024 (actual). Primary completion is estimated for Dec 2050, 320 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Aug 2030 → Dec 2050 and completion Aug 2032 → Dec 2050.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2024
First posted
Apr 8, 2024
StartActual
Apr 9, 2024
Primary completionEst.
Dec 31, 2050was Aug 2030
CompletionEst.
Dec 31, 2050was Aug 2032
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2030→Dec 31, 2050
Nov 18, 2026
Study completion
Aug 31, 2032→Dec 31, 2050
Nov 18, 2026
Enrollment
1500→4500
Nov 18, 2026
Eligibility
Minimum age 18 Years→none; Criteria largely rewritten (15 changes)
What changed in the criteria
Inclusion criteria
  • RemovedAge >18 years old.
  • RemovedThe diagnosis of ACM was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.
  • RemovedPatients or their families agreed to participate in the study and authorized informed consent.
  • AddedPatients of any age or sex with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM), established through comprehensive clinical evaluation based on medical and family history, electrocardiographic findings, cardiac imaging, available genetic testing results, and histopathological findings when clinically indicated. Diagnosis will refer to applicable international guidelines and consensus documents, including the 2019 Heart Rhythm Society expert consensus statement, the 2020 Padua criteria, the 2023 European Society of Cardiology guidelines for cardiomyopathies, and subsequent applicable updates.
  • AddedAvailability of essential clinical information sufficient to confirm the diagnosis of ACM and establish a longitudinal clinical record, including relevant baseline and observation dates.
  • AddedFulfillment of applicable ethical approval and informed consent requirements. For retrospective data collection, participation will be subject to approved consent waiver provisions or existing valid authorization. Prospective participants will provide informed consent through the applicable approved procedures. For minors, permission from a parent or legal guardian and age-appropriate assent will be obtained as required.
Exclusion criteria
  • RemovedIncomplete clinical data.
  • RemovedDo not agree to the inclusion or refuse to authorize the informed consent.
  • AddedACM diagnosis cannot be confirmed after clinical review, or the observed cardiac abnormalities and ventricular arrhythmias can be sufficiently explained by another established disease without meeting the study's diagnostic criteria for ACM.
  • AddedInsufficient essential clinical information to confirm ACM diagnosis or determine the relevant observation period, despite reasonable efforts to verify the available records.
  • AddedRefusal to participate, withdrawal or absence of required authorization, or failure to meet applicable ethical and informed consent requirements.
  • AddedAdditional Considerations:
  • AddedPatients with coexisting diseases, previous ventricular arrhythmias, implantable cardioverter-defibrillators, prior catheter ablation, or heart failure may be eligible if they otherwise meet the study criteria.
  • AddedCardiac magnetic resonance imaging, genetic testing, and biological sample collection are not mandatory for enrollment. The absence of these investigations or samples will not be considered an exclusion criterion.
  • AddedAsymptomatic relatives carrying ACM-associated genetic variants who do not meet the clinical diagnostic criteria for ACM will not be included in the confirmed ACM registry cohort solely on the basis of carrier status.
Nov 18, 2026
Interventions
Arms added: Retrospective Cohort·Prospective Cohort; arms removed: Right ventricular ACM group·Left ventricular ACM group·Biventricular ACM group
Nov 18, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Change in the incidence of mortality rateNow Time to First Composite Serious Ventricular Arrhythmic EventTime frame: At diagnosis, before discharge (about 7 days), 1, 3, 6, 9 month, 1, 2, 3 year. → Time to First Composite Serious Ventricular Arrhythmic Event
Nov 18, 2026
Secondary outcomes
19 added
What changed in the outcomes
  • AddedFirst Occurrence of Sustained Ventricular Tachycardia or Ventricular FibrillationTime frame: 5 years
  • AddedIncidence of Sudden Cardiac DeathTime frame: 5 years
  • AddedFirst Occurrence of Appropriate Implantable Cardioverter-Defibrillator TherapyTime frame: 5 years
  • AddedOccurrence of Heart Failure HospitalizationTime frame: 5 years
  • AddedAll-Cause MortalityTime frame: 5 years
  • AddedCardiovascular MortalityTime frame: 5 years
  • AddedOccurrence of Heart TransplantationTime frame: 5 years
  • AddedInitiation of Long-Term Mechanical Circulatory SupportTime frame: 5 years
  • AddedRate of Recurrent Serious Ventricular Arrhythmic EventsTime frame: 5 years
  • AddedRecurrence of Ventricular Arrhythmia After Catheter AblationTime frame: Up to 5 years
  • AddedProportion of Patients With Changes in Ventricular PhenotypeTime frame: Baseline and up to 5 years
  • AddedChange in Left Ventricular Ejection FractionTime frame: Baseline and up to 5 years
  • AddedChange in Right Ventricular Ejection FractionTime frame: Baseline and up to 5 years
  • AddedChange in Left Ventricular End-Diastolic Volume IndexTime frame: Baseline and up to 5 years
  • AddedChange in Right Ventricular End-Diastolic Volume IndexTime frame: Baseline and up to 5 years
  • AddedPresence of Late Gadolinium Enhancement on Cardiac Magnetic Resonance ImagingTime frame: Baseline and up to 5 years
  • AddedVentricular Distribution of Late Gadolinium EnhancementTime frame: Baseline and up to 5 years
  • Addedother outcomeAssociations Between Biospecimen-Derived Molecular Profiles and Clinical OutcomesTime frame: Baseline and up to 5 years
  • Addedother outcomeExploratory Molecular Signatures Associated With Ventricular Remodeling and ACM PhenotypesTime frame: Baseline and up to 5 years
Nov 18, 2026
Contact
Study contact's phone or email changed: •••3869→•••3865; •••3869→•••3868; l•••@163.com→g•••@xjtu.edu.cn. See the current contact
Nov 18, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • First Affiliated Hospital of Xi'an Jiantong University · Xi'an, ChinaContact •••3869→•••3868Contact l•••@163.com→g•••@xjtu.edu.cnContact •••3869→•••3865
Nov 18, 2026
Title
Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy→Clinical Phenotypes, Natural History, and Long-Term Outcomes of Arrhythmogenic Cardiomyopathy: The STARTER Registry
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Aug 31, 2030→Dec 31, 2050
    Study completion Aug 31, 2032→Dec 31, 2050
    Enrollment 1500→4500
    Eligibility Minimum age 18 Years→none; Criteria largely rewritten (15 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedAge >18 years old.
    • RemovedThe diagnosis of ACM was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.
    • RemovedPatients or their families agreed to participate in the study and authorized informed consent.
    • AddedPatients of any age or sex with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM), established through comprehensive clinical evaluation based on medical and family history, electrocardiographic findings, cardiac imaging, available genetic testing results, and histopathological findings when clinically indicated. Diagnosis will refer to applicable international guidelines and consensus documents, including the 2019 Heart Rhythm Society expert consensus statement, the 2020 Padua criteria, the 2023 European Society of Cardiology guidelines for cardiomyopathies, and subsequent applicable updates.
    • AddedAvailability of essential clinical information sufficient to confirm the diagnosis of ACM and establish a longitudinal clinical record, including relevant baseline and observation dates.
    • AddedFulfillment of applicable ethical approval and informed consent requirements. For retrospective data collection, participation will be subject to approved consent waiver provisions or existing valid authorization. Prospective participants will provide informed consent through the applicable approved procedures. For minors, permission from a parent or legal guardian and age-appropriate assent will be obtained as required.
    Exclusion criteria
    • RemovedIncomplete clinical data.
    • RemovedDo not agree to the inclusion or refuse to authorize the informed consent.
    • AddedACM diagnosis cannot be confirmed after clinical review, or the observed cardiac abnormalities and ventricular arrhythmias can be sufficiently explained by another established disease without meeting the study's diagnostic criteria for ACM.
    • AddedInsufficient essential clinical information to confirm ACM diagnosis or determine the relevant observation period, despite reasonable efforts to verify the available records.
    • AddedRefusal to participate, withdrawal or absence of required authorization, or failure to meet applicable ethical and informed consent requirements.
    • AddedAdditional Considerations:
    • AddedPatients with coexisting diseases, previous ventricular arrhythmias, implantable cardioverter-defibrillators, prior catheter ablation, or heart failure may be eligible if they otherwise meet the study criteria.
    • AddedCardiac magnetic resonance imaging, genetic testing, and biological sample collection are not mandatory for enrollment. The absence of these investigations or samples will not be considered an exclusion criterion.
    • AddedAsymptomatic relatives carrying ACM-associated genetic variants who do not meet the clinical diagnostic criteria for ACM will not be included in the confirmed ACM registry cohort solely on the basis of carrier status.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Change in the incidence of mortality rateNow Time to First Composite Serious Ventricular Arrhythmic EventTime frame: At diagnosis, before discharge (about 7 days), 1, 3, 6, 9 month, 1, 2, 3 year. → Time to First Composite Serious Ventricular Arrhythmic Event
    Secondary outcomes 19 added
    What changed in the outcomes
    • AddedFirst Occurrence of Sustained Ventricular Tachycardia or Ventricular FibrillationTime frame: 5 years
    • AddedIncidence of Sudden Cardiac DeathTime frame: 5 years
    • AddedFirst Occurrence of Appropriate Implantable Cardioverter-Defibrillator TherapyTime frame: 5 years
    • AddedOccurrence of Heart Failure HospitalizationTime frame: 5 years
    • AddedAll-Cause MortalityTime frame: 5 years
    • AddedCardiovascular MortalityTime frame: 5 years
    • AddedOccurrence of Heart TransplantationTime frame: 5 years
    • AddedInitiation of Long-Term Mechanical Circulatory SupportTime frame: 5 years
    • AddedRate of Recurrent Serious Ventricular Arrhythmic EventsTime frame: 5 years
    • AddedRecurrence of Ventricular Arrhythmia After Catheter AblationTime frame: Up to 5 years
    • AddedProportion of Patients With Changes in Ventricular PhenotypeTime frame: Baseline and up to 5 years
    • AddedChange in Left Ventricular Ejection FractionTime frame: Baseline and up to 5 years
    • AddedChange in Right Ventricular Ejection FractionTime frame: Baseline and up to 5 years
    • AddedChange in Left Ventricular End-Diastolic Volume IndexTime frame: Baseline and up to 5 years
    • AddedChange in Right Ventricular End-Diastolic Volume IndexTime frame: Baseline and up to 5 years
    • AddedPresence of Late Gadolinium Enhancement on Cardiac Magnetic Resonance ImagingTime frame: Baseline and up to 5 years
    • AddedVentricular Distribution of Late Gadolinium EnhancementTime frame: Baseline and up to 5 years
    • Addedother outcomeAssociations Between Biospecimen-Derived Molecular Profiles and Clinical OutcomesTime frame: Baseline and up to 5 years
    • Addedother outcomeExploratory Molecular Signatures Associated With Ventricular Remodeling and ACM PhenotypesTime frame: Baseline and up to 5 years
    Interventions Arms added: Retrospective Cohort·Prospective Cohort; arms removed: Right ventricular ACM group·Left ventricular ACM group·Biventricular ACM group
    Contact Study contact's phone or email changed: •••3869→•••3865; •••3869→•••3868; l•••@163.com→g•••@xjtu.edu.cn. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • First Affiliated Hospital of Xi'an Jiantong University · Xi'an, ChinaContact •••3869→•••3868Contact l•••@163.com→g•••@xjtu.edu.cnContact •••3869→•••3865
    Title Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy→Clinical Phenotypes, Natural History, and Long-Term Outcomes of Arrhythmogenic Cardiomyopathy: The STARTER Registry
    + 5 other changes: index terms, verification date, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06352307
Responsible party
Sponsor
First posted
Apr 8, 2024
Start date
Apr 9, 2024
Primary completion
Dec 31, 2050 (estimated)
Completion
Dec 31, 2050 (estimated)
Last update
Nov 18, 2026

Study contacts

Guoliang Li
Contact
guoliangli@xjtu.edu.cn
0086-2985323868
Yang Yan
Contact
yangyan3@xjtu.edu.cn
0086-2985323865
Guoliang Li
principal investigator · First Affiliated Hospital Xi'an Jiaotong University
Yang Yan
principal investigator · First Affiliated Hospital Xi'an Jiaotong University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion